Skip to main content
KYMR logo

KYMR · Kymera Therapeutics, Inc. · Investor Relations

Track KYMR — free
$115.31 -4.08 (-3.42%) At close · Nov 20 Q3 2026 earnings call transcript
Market Cap
$9.84B
Shares
85.37M
Volume · Nov 20 1.28M Avg daily vol (3M) 847.26K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-11-23 13:00 UTC Kymera Therapeutics KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results Earnings call

Recent news

Date Headline
2026-10-29 Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
2026-10-28 Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
2026-10-22 Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
2026-08-05 Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
2026-07-27 Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
2026-06-25 Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
2026-04-30 Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
2026-02-26 Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
2026-01-13 Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
2025-12-10 Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
2025-12-10 Kymera Therapeutics Announces Proposed Public Offering
2025-12-08 Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
2025-11-04 Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update

Past events

Date Event Type
2026-10-29 Kymera Therapeutics Third Quarter 2026 Quarterly Results Call Earnings call
2026-09-24 Stifel 2026 Virtual Immunology and Inflammation Forum Webcast
2026-09-15 Morgan Stanley 24th Annual Global Healthcare Conference Conference
2026-09-14 H.C. Wainwright 28th Annual Global Investment Conference Conference
2026-09-10 Citi 2026 Biopharma Back to School Summit Webcast
2026-09-09 Wells Fargo 21st Annual Healthcare Conference Conference
2026-08-05 Q2 FY2026 Earnings conference call (announced in 8-K) Earnings call
2026-08-05 Kymera Therapeutics Second Quarter 2026 Results Call | August 5, 2026 Earnings call
2026-06-03 Jefferies Global Healthcare Conference Conference
2026-05-19 RBC Capital Markets 2026 Global Healthcare Conference Conference
2026-05-12 Bank of America 2026 Healthcare Conference Conference
2026-04-30 Kymera Therapeutics First Quarter 2026 Quarterly Results Call Earnings call
2026-04-30 Kymera Therapeutics First Quarter 2026 Results Call Earnings call
2026-03-12 Barclays 28th Annual Global Healthcare Conference Conference
2026-03-11 Jefferies Biotech on the Beach Summit Event
2026-03-10 Leerink Partners Global Healthcare Conference Conference
2026-03-09 UBS Biotech Summit Miami Event
2026-03-03 TD Cowen 46th Annual Healthcare Conference Conference
2026-02-26 Earnings conference call (announced in 8-K) Earnings call
2026-02-26 Oppenheimer Virtual 36th Annual Healthcare Life Sciences Conference Conference
2025-11-04 Kymera Therapeutics Third Quarter 2025 Results Call | November 4, 2025 Earnings call
2025-08-11 Kymera Therapeutics Second Quarter 2025 Results Call | August 11, 2025 Earnings call
2025-05-09 Kymera Therapeutics Immunology Innovation Day | May 9, 2025 Earnings call

Source: https://investors.kymeratx.com/

Key facts CIK 1815442 CUSIP 501575104 13F (30d) 320 filings 293 filers Visit website Investor relations